Posts

Shutterstock.com

FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics

This trial, using Filament Health's botanical drug candidates, is the first to assess the direct administration of psilocin.

Psychedelic Business Spotlight: October 29

,
This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
FDA Authorizes Device to Quantify Psychedelics’ Effects on the BrainShutterstock.com

FDA Authorizes Cybin Device to Quantify Psychedelics’ Effects on the Brain

"This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," says Cybin's chief clinical officer.
FDA Green Lights Ketamine for Treatment of ALS

FDA Green Lights Ketamine for Treatment of ALS

,
"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine," says PharmaTher CEO Fabio Chianelli.